Georgia's Online Cancer Information Center

Neuroendocrine Tumor Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Neuroendocrine Tumor
Cancer Type = Neuroendocrine Tumor
There are currently 11 active Neuroendocrine Tumor clinical trials in Georgia.
1.
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
Cancer Type
Neuroendocrine Tumor, Prostate Cancer , Unknown Primary
NCT ID
NCT04702737
Protocol IDs
20200040
NCI-2021-08862
2.
A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (1)
3.
A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma
Cancer Type
Gynecologic Cancers, Lung Cancer, Lymphoma, Neuroendocrine Tumor, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor
NCT ID
NCT02922764
Protocol IDs
RGX-104-001
NCI-2017-00226
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Cancer Type
Head and Neck Cancer, Neuroendocrine Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT04211337
Protocol IDs
17478
NCI-2020-00277
2019-001978-28
J2G-MC-JZJB
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Cancer Type
Bile Duct Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Neuroendocrine Tumor, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCT ID
NCT02568267
Protocol IDs
RXDX-101-02
NCI-2015-01848
Treatment Sites (2)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
Cancer Type
Lung Cancer, Neuroendocrine Tumor, Unknown Primary
NCT ID
NCT04265534
Protocol IDs
CX-839-014
NCI-2020-04529
Treatment Sites (4)
Piedmont Cancer Institute - Atlanta
Atlanta
Katie Adams
678-298-3238
Piedmont Cancer Institute - Fayetteville
Fayetteville
678-298-3238
Piedmont Cancer Institute - Newnan
Newnan
Katie Adams
678-298-3238
Piedmont Cancer Institute - Stockbridge
Stockbridge
Katie Adams
678-298-3238
7.
Nivolumab and Ipilimumab in Treating Patients with Advanced Rare Genitourinary Tumors
Cancer Type
Adrenal Cancer, Bladder Cancer, Neuroendocrine Tumor, Penile Cancer, Prostate Cancer , Unknown Primary
NCT ID
NCT03333616
Protocol IDs
17-423
NCI-2018-00182
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
NCORP Trial
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type
Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain Tumor, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Mesothelioma, Neuroendocrine Tumor, Ovarian Cancer, Parathyroid Cancer, Penile Cancer, Retroperitoneal Tumors, Sarcoma, Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT02834013
Protocol IDs
S1609
NCI-2016-01041
Treatment Sites (10)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Piedmont Fayette Hospital
Fayetteville
404-851-2340
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy in Treating Patients with Recurrent or Stage IV Merkel Cell Cancer
Cancer Type
Neuroendocrine Tumor, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03071406
Protocol IDs
MCC-18786
NCI-2017-00427
10.
NCORP Trial
Pembrolizumab Compared to Standard of Care Observation in Treating Patients with Completely Resected Stage I-III Merkel Cell Cancer, STAMP Study
Cancer Type
Neuroendocrine Tumor, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03712605
Protocol IDs
EA6174
EA6174
NCI-2018-02217
Treatment Sites (1)
11.
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Neuroendocrine Tumor, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04579757
Protocol IDs
2020-012-GLOB1
NCI-2021-01887
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.